TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00996437

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Intravitreal injection of 0.5 mg ranibizumab (Lucentis™) at baseline, 4 and 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline injection of 0.5mg at baseline, 4 and 8 weeks
Study: NCT03439631

Intervention type: OTHER
Group type: OTHER
Intervention: Patient satisfaction questionnaire
Description: Patient satisfaction questionnaire

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient satisfaction questionnaire
Description: Patient satisfaction questionnaire
Study: NCT01783652

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: Participants in the intervention group will have access to the anti-depression website modified and translated by the University of Hong Kong. 10 chapters on understanding depression, identifying depression symptoms and techniques tackling depression will be covered. Exercises and built-in questionnaires on measuring emotions will be provided in the website. Additional telephone follow-up counseling at the third, sixth and twelfth months will be conducted.
Study: NCT04430127

Intervention type: OTHER
Intervention: No supplementary intervention is performed
Description: No supplementary intervention will be applied
Study: NCT00682552

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: A cervico-vaginal cervical smear
Description: 12 and 18 months after inclusion, a cervico-vaginal cervical smear will be realized and a new examination colposcopique with a new cervical taking for the search(research) and the detection of the HPV 16 and 18.
Study: NCT03206567

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutrafol Supplement capsules
Description: NUTRAFOL's Synergen Complex® is a patent-pending formulation of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant and DHT-inhibiting properties - combined to synergistically combat the multiple underlying factors that compromise hair growth and health. Some patented ingredients include Sensoril Ashwagandha, BCM-95 BioCurcumin, USPlus Saw Palmetto, EVNolMax 20% Tocotrienol/Tocopherol complex, Bioperine (piperine), Cynatine HNS (solubilized keratin), and Capsimax (capsaicin), all of which are standardized and clinically tested. the Nutrafol supplement capsules are compared to the placebo capsules which contain no active ingredients. Four (4) capsules are taken by mouth once daily with a substantial meal.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: The placebo capsules contain no active ingredients. Four (4) capsules are taken by mouth once daily with a substantial meal.
Study: NCT04045808

Intervention type: OTHER
Intervention: radiographic evaluations were done
Description: For radiographic analysis, periapical radiographs were taken from teeth with ≥ 4mm PPD using a hand held intra-oral x-ray system operating at 60kVp, 1.5 mA . The alveolar bone loss was measured by a personal computer with the Microsoft Windows XP operating system with original software.

Intervention type: OTHER
Intervention: radiographic evaluations were done
Description: For radiographic analysis, periapical radiographs were taken from teeth with ≥ 4mm PPD using a hand held intra-oral x-ray system operating at 60kVp, 1.5 mA . The alveolar bone loss was measured by a personal computer with the Microsoft Windows XP operating system with original software.
Study: NCT04214665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha Lipoic acid 600 mg HR film coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha Lipoic acid 600 mg HR film coated tablets
Study: NCT02419924

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the Bottom's Up
Description: A modified toilet seat that supports the perineum, preventing excessive pelvic floor descent and laxity which can cause constipation.
Study: NCT03253094

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole
Description: Oral Antifungal comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCY-078
Description: Investigational Antifungal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCY-078
Description: Investigational Antifungal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCY-078
Description: Investigational Antifungal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCY-078
Description: Investigational Antifungal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCY-078
Description: Investigational Antifungal
Study: NCT00128193

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MLSA-LAM
Description: Mycobacterium leprae soluble antigen with minimal amounts of immunosuppressive lipoglycans; dosages 0.1 and 1.0 micrograms; administered in sterile diluent 0.9% saline (NaCl).
Study: NCT02004184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: maintenance pemetrexed
Description: 500 mg/m2 Body Surface Area is administered intravenously every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed at progression
Description: 500 mg/m2 Body Surface Area is administered intravenously every 3 weeks
Study: NCT02555982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOTOX ® 200 Unités
Description: Patients eligible for inclusion will be randomized to one of the two groups:~* Experimental group: 60 patients will receive 2 injections of Btx A (BOTOX - Allergan), one on D0 and one at 12W (into each splenius capitis).~* Control group: 60 patients will receive 2 injections of placebo, one on D0 and one at 12W (into each splenius capitis).

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Control group: 60 patients will receive 2 injections of placebo, one on D0 and one at 12W (into each splenius capitis).
Study: NCT01551147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-6950
Description: 200 mg QD for 8 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match ONO-6950 tablets or over-encapsulated Montelukast tablets dosed in a similar manner

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: 10 mg Montelukast QD for 8 days
Study: NCT01938235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Intravenous bolus and 24-hour infusion of exenatide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous bolus and 24-hour infusion of placebo
Study: NCT01049347

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amitriptyline
Description: 150 mg oral, daily, single evening dose, 35 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paroxetine
Description: 40 mg oral, single dose, morning, 35 days
Study: NCT01331577

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Training
Description: Two day seminar

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrative Kinesiology Intervention
Description: Two day seminar
Study: NCT04546048

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength Exercise Training
Description: The 8-week exercise-training program consisted of two 30-min sessions a day for 5 days/week and conducted by elastic exercise bands in 2-3 sets, 6-10 repetitions, with 1-2 min rest between sets (M. Deltoideus and M. Quadriceps are trained as major muscle groups). The 8-repetition maximum(8RM) is used to determine training loads with the rated perceived exertion(RPE) lower than 5-7 on the Modified Borg scale(MBS). The program consisted functional exercises by half squat to squat and sit-to-stand chair exercises. Exercise sessions were supervised twice daily during the 1st week, the 2nd week training included one supervised and one unsupervised daily sessions. The remaining 6-week training program conducted at home individually after discharge. Patients instructed for the ongoing 8-week training program and a patient-specific schedule delivered to subjects. Phone calls are provided weekly and training load is assessed while generating 4th week evaluations.
Study: NCT01868282

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hamstrings block
Description: patients enrolled in the study will receive subsartorial saphenous nerve block in all the three groups. Patients in group 1 will receive perimuscular injections around the gracilis and semi-tendinosus muscles. The needle is redirected to the fascial plane between Sartorius and gracilis muscle after the sub-sartorial canal block where 7.5 ml of 0.5% ropivacaine is injected around the muscle. The needle is further advanced to the fascial planes between semimembranosus and semitendinosus and an additional 7.5 ml of 0.5% ropivacaine will be injected around the semitendinosus muscle. Following this a sham injection of 10mL of saline for the anterior division of obturator nerve will also be performed as in group 2 to ensure blinding.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Obturator block
Description: Patients in group 2 will receive anterior division of obturator nerve block along with subsartorial canal block. After ensuring aseptic precautions, the saphenous nerve block is performed similar to that as in group 1. The anterior branch of obturator nerve will be visualised in the proximal thigh medial to femoral vessels between adductor longus and adductor brevis. A 22 gauge 90 mm PNS block needle will be inserted under ultrasound guidance to reach the anterior division of obturator nerve confirmed with neurostimulation followed by injection of 10 ml of 0.5% ropivacaine around the nerve. This group will receive sham injection of 15mL of saline around semitendinosus and semimembranosus as in group 1

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: The patients in group 3 will form the control group. After performance of the subsartorial saphenous nerve block, patients in group 3 will receive sham injections of saline for the obturator nerve block and the hamstrings block (perimuscular injections).
Study: NCT01142531

Intervention type: RADIATION
Intervention: Chest CT scan
Description: Supine CT scan after full inspiration. Acquisition parameters: (Topogram 35 mA 120 kV 512 mm length)~* 90 quality ref mAs with care-dose ON~* 120 kV~* Pitch 1.4~* Rotation time 0.33 s~* Acquired images 64 x 0.6 mm
Study: NCT01832402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Pectin Nasal Spray
Description: Fentanyl pectin nasal (FPNS) dose equivalent to 15-25% of the morphine equivalent daily dose (MEDD) administered intranasally 20 minutes before the second 6-minute walk test. Same dose repeated at least 30 minutes after the first dose and 20 minutes prior to the third and final 6 minute walk test.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nasal Spray
Description: Placebo nasal spray administered intranasally 20 minutes before the second 6-minute walk test. Same dose repeated at least 30 minutes after the first dose and 20 minutes prior to the third and final 6 minute walk test.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walk Test
Description: Walk test administered before first dose of drug/placebo nasal spray. Participant will rest for 30 minutes after walk test. Drug/placebo nasal spray administered, then participant will wait 20 minutes before repeating second 6 minute walk test. After second walk test, participant will rest for 30 minutes. Drug/placebo nasal spray administered for second time, then participant will wait for 20 minutes. Walk test administered again for 6 minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Walk Test
Description: Walk test administered before first dose of drug/placebo nasal spray. Participant will rest for 30 minutes after walk test. Drug/placebo nasal spray administered, then participant will wait 20 minutes before repeating second 6 minute walk test. After second walk test, participant will rest for 30 minutes. Drug/placebo nasal spray administered for second time, then participant will wait for 20 minutes. Walk test administered again for 6 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires completed at baseline, before each walk test, and at end of final walk test.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaires
Description: Questionnaires completed at baseline, before each walk test, and at end of final walk test.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental Ability Tests
Description: Four mental ability tests administered after each walk test to include finger tapping, simple mathematics questions, recall of numbers, and recall of objects.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Mental Ability Tests
Description: Four mental ability tests administered after each walk test to include finger tapping, simple mathematics questions, recall of numbers, and recall of objects.
Study: NCT01694082

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: THRIVE
Description: THRIVE stands for (Tertiary Health Research Intervention Via Email). Participants complete questions related to demographics and their alcohol use and receive brief personalized feedback based on this information, in addition to protective behavioral strategies, facts about alcohol and information about available resources to reduce their alcohol use.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: THRIVE
Description: THRIVE stands for (Tertiary Health Research Intervention Via Email). Participants complete questions related to demographics and their alcohol use and receive brief personalized feedback based on this information, in addition to protective behavioral strategies, facts about alcohol and information about available resources to reduce their alcohol use.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: THRIVE
Description: THRIVE stands for (Tertiary Health Research Intervention Via Email). Participants complete questions related to demographics and their alcohol use and receive brief personalized feedback based on this information, in addition to protective behavioral strategies, facts about alcohol and information about available resources to reduce their alcohol use.
Study: NCT04749615

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Periarticular Injection (PAI)
Description: PAI is a widely-utilized, surgeon-performed, analgesic intervention for TKA patients.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Control Periarticular Injection (PAI)
Description: equal volume of saline will be used in place of analgesics used in PAI injections
Study: NCT03605693

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Written Exposure Therapy
Description: Written exposure therapy is a 5 session treatment in which participants write about their trauma event in a specified manner.
Study: NCT00216190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine HCL Injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam Injection
Study: NCT02303262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mocetinostat
Description: Mocetinostat is taken orally at 70 mg/dose, 3 days per week, during cycle 1. Dose is increased to 90 mg starting at cycle 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine is administered via intravenous infusion at 1,000 mg/m2 at a rate of approximately 10 mg/m2/minute, on days 5 and 12 of every cycle.
Study: NCT00128193

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MLCwA
Description: Cell wall-associated proteins of Mycobacterium leprae; dosages 0.1 and 1.0 micrograms; administered in sterile diluent 0.9% saline (NaCl).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MLCwA
Description: Cell wall-associated proteins of Mycobacterium leprae; dosages 0.1 and 1.0 micrograms; administered in sterile diluent 0.9% saline (NaCl).
Study: NCT04152239

Intervention type: PROCEDURE
Intervention: Motorized spiral enteroscopy (MSE)
Description: Endoscopic Procedures MSE is a 1.6m enteroscope equipped with a single-use short spiral overtube propelled by a user-controlled motor contained in the handle of the endoscope. The endoscopist controls the left-right and up-down movements by the usual manuvers while the forward or backward advancement of the enteroscope would be contolled by a foot pedal that activates the spiral overtube rotation. Antegrade MSE, retrograde MSE, or combined antegrade and retrograde MSE would be performed as clinically indicated for diagnostic +/- therapeutic procedures.
Study: NCT01644435

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Autologous Human Platelet Lysate
Description: Subjects will receive a single injection of Autologous Human Platelet Lysate for acne scarring

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Autologous Human Platelet Lysate
Description: Subjects will receive two injections of Autologous Human Platelet Lysate at an interval of one month for acne scarring
Study: NCT02363166

Intervention type: OTHER
Intervention: Acute Abscess Group
Description: Samples collected for culture and sensitivity testing depending on acute abscess, or skin/soft tissue infection.
Study: NCT02247921

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: Patients recruited into the intervention arm will have their family-nominated caregivers trained by a trained nurse and guided by a culturally appropriate and easy-to-understand rehabilitation manual to be given to caregivers at the last session, shortly before hospital discharge to reduce contamination. The training sessions will take at least 90 minutes per day for 2 or 3 days.The nurse will call the patients and caregivers at 2, 4, and 8 weeks after hospital discharge to monitor progress and offer guidance on rehabilitation.Duration of the standardized yet individualized intervention by nurses will be 8 weeks; however, trained caregivers are expected to deliver the rehabilitation services to patients as long as they are needed.
Study: NCT03560388

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture and touch/relaxation
Description: Pre-operative integrative care (touch-relaxation) that follows with intra-operative acupuncture

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture and touch/relaxation
Description: Pre-operative integrative care (touch-relaxation) that follows with intra-operative acupuncture
Study: NCT04770207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of drug-eluting microspheres with multiple drugs into solid tumors
Description: Under the guidance of CT, puncture fine needle was used to inject drug-eluting microspheres loading with multiple drugs into the tumor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of drug-eluting microspheres with multiple drugs into solid tumors
Description: Under the guidance of CT, puncture fine needle was used to inject drug-eluting microspheres loading with multiple drugs into the tumor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of drug-eluting microspheres with multiple drugs into solid tumors
Description: Under the guidance of CT, puncture fine needle was used to inject drug-eluting microspheres loading with multiple drugs into the tumor
Study: NCT01694082

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Brief brochure and assessment control
Study: NCT03700645

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: Allopurinol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: Allopurinol
Study: NCT01594359

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biofortified beans
Description: Comparison of two types of the common bean that are similar in all aspects except their iron concentration - one has a high iron concentration while the other has low iron concentration

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: BEAN
Description: Placebo
Study: NCT03509571

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet
Description: Enteral feeding via nasogastric (NG) or nasojejunal (NJ) tubes with ketogenic diet will start within 72 hours of injury and solid feeding will start as soon as the patient is able to swallow. This diet is a high-fat, low-carbohydrate diet (lipid to carbohydrate + protein ratio of 3:1) that will include ≈75% total energy as fat, ≈20% as protein, and ≈5% as carbohydrate and fiber.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Diet
Description: Enteral feeding via nasogastric (NG) or nasojejunal (NJ) tubes with SD diet will start within 72 hours of injury and solid feeding will start as soon as the patient is able to swallow. This diet includes ≈35% total energy as fat, ≈27% as protein, and ≈44% as carbohydrate and fiber.
Study: NCT00108082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carvedilol MR
Description: Study drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atenolol
Description: Comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lisinopril
Description: Comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lisinopril
Description: Comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lisinopril
Description: Comparator
Study: NCT03340987

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vestibular incision subperiosteal tunnel access
Description: vertical vestibular incision will be made down to the periosteum followed by creating a tunnel without reflecting the interdental papilla. Then a free gingival graft will be optained from the palate and de-epithelialized extraorally. The connective tissue graft will then be applied through the tunnel and the gingival margin will be sutured and the sutures will be fixed to the tooth surface by flowable composite. Then the vestibular incision will be sutured.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronally advanced flap
Description: Two horizontal incisions will be made mesial and distal to the recession area followed by two oblique incisions extended to the alveolar mucosa and a full-split thickness flap will be elevated. De-epithelialization will be done to receive the connective tissue graft obtained from the palate by de-epithelializing a free gingival graft. Then the flap will be advanced coronally aand sutured without tension
Study: NCT02558465

Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Treatment parameters following the summary of product characteristics and the physician's decision